Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose dose-escalation study of MORAb-022 in healthy volunteers and rheumatoid arthritis patients
NL-OMON34310Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of gimsilumab in rheumatoid arthritis (RA) (9 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability, Pharmacokinetics of MORAb-022 and 2 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
gimsilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34310.